Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05250063 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

A Phase 2 study of Growth Hormone Deficiency, sponsored by Lumos Pharma.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target
10
Study locations

NCT05250063 is a Phase 2 study of Growth Hormone Deficiency that has completed, run by Lumos Pharma. The registered enrollment target is 18 participants, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05250063, a Phase 2 study of Growth Hormone Deficiency, has completed, sponsored by Lumos Pharma.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target
10
Study locations

Study Summary

This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.

Conditions Studied

Growth Hormone Deficiency

Interventions

  • DRUG LUM-201

Study Locations (10)

Other

  • Klinika Endokrynologii i Chorob Metabolicznych, Instytut Centrum Zdrowia Matki Polki - Lodz
  • Sonomed - Centrum Medyczne - Szczecin
  • Klinika Endokrynologii i Diabetologii, Instytut "Pomnik Centrum Zdrowia Dziecka - Warsaw

California

  • Rady Children's Hospital - San Diego

District of Columbia

  • Children's National Hospital - Washington D.C.

Indiana

  • Indiana University School of Medicine - Indianapolis

Minnesota

  • M Health, Fairview Pediatric Specialty Clinics- Discovery Clinic - Minneapolis

Missouri

  • The Children's Mercy Hospital - Kansas City

Ohio

  • Nationwide Children's Hospital - Columbus

Virginia

  • University of Virginia Health System - Charlottesville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2022-02-18
Est. Completion 2025-01-22
Phase Phase 2

Sponsor

Lumos Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05250063

The ClinicalTrials.gov registry entry for NCT05250063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The listed sponsor is Lumos Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which LUM-201 is the first listed.

NCT05250063 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Other, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05250063 about?

NCT05250063 is a clinical study titled "Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)". This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.

What is the current status of trial NCT05250063?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-02-18. Estimated completion is 2025-01-22.

What conditions does trial NCT05250063 study?

This clinical trial studies the following conditions: Growth Hormone Deficiency.

What interventions are being tested in trial NCT05250063?

The interventions under investigation include: LUM-201 (DRUG).

Who is sponsoring clinical trial NCT05250063?

This trial is sponsored by Lumos Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05250063 being conducted?

This trial has 10 study locations across California, District of Columbia, Indiana, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Growth Hormone Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Growth Hormone Deficiency

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.